Lurbinectedin With Irinotecan In Relapsed Small Cell Lung Cancer. Results From The Expansion Stage Of A Phase I-Ii Trial

Lurbinectedin is a novel anti-cancer agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of the tumor microenvironment. In June 2020, the US FDA granted accelerated approval to lurbinectedin (ZepzelcaTM) for the treatment of adult patients (pts) with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy based on the results of a phase II study (Trigo et al. Lancet Oncol 2020). Preclinical evidence of synergism was observed for lurbinectedin in combination with irinotecan.